Multiple Myeloma Treatment Evolution in Transplant-Ineligible Patients

By The Fellow on Call - Last Updated: August 1, 2023

In part six of the Myeloma Series, a historical perspective on the treatment evolution of myeloma and a discussion on treating transplant-ineligible patients with multiple myeloma.

Questions investigated in this podcast episode include the following:

How has the treatment evolved in transplant ineligible patients?
Why is triplet regimen the standard of care in transplant ineligible patients?
What is the trial that led to quadruplet therapy?
What is the MAIA trial?

How to Approach Relapsed DLBCL After CAR-T Therapy

What to Know About Relapsed Disease Treatment After 12 Months in DLBCL

How to Approach Patients with Primary Refractory DLBCL

How Is Cellular Therapy Changing Care for Hematologic Malignancies?

How Has Treatment for Advanced DLBCL Evolved?

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Multiple Myeloma Treatment Evolution in Transplant-Ineligible Patients

Related